Summary
Date: 15 October 2021
The Royal Australian College of General Practitioners thanks the Department of Health for the opportunity to respond to the MSAC 1677 Pharmacy Diabetes Screening trial. The RACGP supports efforts to improve the identification and management of people with diabetes. However, the evidence-base underpinning the screening protocol in this pharmacy trial has raised concerns. In addition there are concerns about the study design and lack of reported data. The proposed model of screening for type 2 diabetes in the pharmacy setting is an inequitable model of care that limits availability of the service and may fragment patient care.